Summarized by Daily Strand AI from peer-reviewed source
One of the biggest unsolved problems in gene therapy is getting the medicine past a cellular bouncer called the endosome. When a lipid nanoparticle (LNP), a tiny fat-coated bubble used to carry genetic cargo like mRNA or CRISPR gene-editing tools into cells, gets swallowed by a cell, it often ends up trapped inside compartments called endosomes and lysosomes, where it gets degraded before it can do its job. Escaping this trap, known as endosomal escape, is a critical step that has been notoriously hard to measure or improve, especially inside a living animal. Now, researchers have developed a new class of lipid particles called branched ionizable phospholipids, with a lead compound called BiP-20, that dramatically improves this escape process in liver cells.
The team tested BiP-20 against LP01, a well-established clinical standard used in approved medicines, and found it performed eight times better at editing the TTR gene using CRISPR-Cas9 at low doses. The TTR gene is linked to a serious disease called transthyretin amyloidosis, where misfolded proteins accumulate and damage the heart and nerves. To actually measure how many particles were escaping the cellular traps in a living mouse, the researchers used a specialized mouse model called LysoTag mice, which allow scientists to isolate liver lysosomes, combined with a new technique they call Lysosomal Barcoding. Using this approach, they found that about 8% of BiP-20 particles successfully escaped into the cell's interior, called the cytosol, within just 30 minutes of being injected. They also discovered that a protein called Rab7, which normally helps mature these cellular traps, actually hinders escape, and that removing it allowed more particles to get through.
Medicines that rely on delivering RNA or gene-editing tools into cells, including mRNA vaccines, CRISPR therapies, and RNA-based drugs for liver diseases, all face the same fundamental bottleneck at the endosome. Improving endosomal escape even modestly could mean lower doses, fewer side effects, and broader access to these therapies. BiP-20's eightfold improvement over a clinical benchmark like LP01 at low doses is a notable leap, particularly for diseases like transthyretin amyloidosis, which currently affects tens of thousands of patients in the United States and can cost hundreds of thousands of dollars per year to treat with existing medicines. Beyond any single compound, the Lysosomal Barcoding method developed here gives researchers a new tool to measure something that was previously almost impossible to quantify inside a living animal, which could accelerate development across the entire field of RNA therapeutics. It is important to note that all findings so far come from preclinical mouse models, and further validation will be needed before these results can be applied to human patients.
Interested in Gene Therapy?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.